MKC 231

a tetrahydrofuroquinoline analog; a choline uptake enhancer; structure given in first source

Also Known As:

2-(2-oxypyrrolidin-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro(2,3-b)quinolin-4-yl)acetoamide; MKC-231

Networked: 5 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - MKC 231: 5

Experts

1.	Lin, Meng-Juan: 1 article (01/2018)
2.	Yu, Bao-Ping: 1 article (01/2018)
3.	Katayama, Seiji: 1 article (09/2007)
4.	Kawahara, Ryuzou: 1 article (09/2007)
5.	Nishimura, Tomoko: 1 article (09/2007)
6.	Shirayama, Yukihiko: 1 article (09/2007)
7.	Yamamoto, Ayaka: 1 article (09/2007)

Related Diseases

1.	Tremor (Tremors) 04/01/1996 - "Oral administration of MKC-231 (1-10 mg/kg) significantly improved the learning deficits in the Morris' water maze of AF64A-treated rats, but it did not produce any significant side effects, like tremor, salivation or hypothermia, which were observed in rats treated with high doses of tacrine. "
2.	Memory Disorders (Memory Loss) 01/01/1994 - "In acute behavioral experiments, MKC-231 and THA had no significant effect on AF64A-induced memory deficits at any doses tested (0.3, 1.0 and 3.0 mg/kg), whereas Dup 996, at a dose of 1.0 mg/kg, significantly improved memory deficits. " 01/01/1994 - "In chronic experiments, MKC-231 improved memory deficit at all doses tested (0.3, 1.0, or 3.0 mg/kg p.o., once daily for 11 days) and Dup 996 did so only at a dose of 3.0 mg/kg, whereas THA did not improve memory deficit at any doses tested. "
3.	Hypothermia 04/01/1996 - "Oral administration of MKC-231 (1-10 mg/kg) significantly improved the learning deficits in the Morris' water maze of AF64A-treated rats, but it did not produce any significant side effects, like tremor, salivation or hypothermia, which were observed in rats treated with high doses of tacrine. "
4.	Hyperalgesia 01/01/2023 - "MKC-231 has potential for treating disorders accompanied by hyperalgesia." 01/01/2018 - "MKC-231 could be used as a potential drug to treat disorders with hyperalgesia." 01/01/2023 - "Furthermore, microglial activation in the spinal dorsal horn promoted the stress-induced hyperalgesia, and MKC-231 achieved analgesic effects by inhibiting the spinal microglial activation. " 01/01/2023 - "Spinal acetylcholine (ACh) was measured by ELISA; the influence of spinal CHT1 on hyperalgesia were evaluated by intrathecal administration of MKC-231 (a choline uptake enhancer) and hemicholinium-3 (HC-3, a specific inhibitor of CHT1). "
5.	Visceral Pain 01/01/2018 - "Pharmacologic enhancement of CHT1 activity by MKC-231 gavage could relieve the visceral pain of WAS rats by upregulating CHT1 protein expression and enhancing ACh production. " 01/01/2018 - "Effects of MKC-231, a choline uptake enhancer, on visceral pain were examined. "

Related Drugs and Biologics

1.	Tacrine (Cognex)
2.	linopirdine
3.	Choline (Choline Chloride)
4.	Proteins (Proteins, Gene)
5.	Analgesics (Analgesic Drugs)
6.	Acetylcholine (Acetylcholine Chloride)

Related Therapies and Procedures

1.	Oral Administration